FDA Urged To Emphasize Post-Market Safety Monitoring Over Pre-Approval Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency’s drug approval system places too much emphasis on pre-approval testing and not enough on post-marketing surveillance, Stanford University Center for Health Policy Director Garber suggests. Vioxx is the most recent example of safety problems not evident until after widespread use, he says.
You may also be interested in...
CMS To Fund Clinical Trials Evaluating Off-Label Use Of Avastin, Erbitux
Under the agency’s proposed national coverage decision for colorectal therapies, CMS will fund costs of experimental drugs and routine care in nine National Cancer Institute trials. Use of Avastin in patients with colorectal cancer in the adjuvant setting and use of Erbitux in head and neck cancers are among the indications being studied in the NCI trials.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said